Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study. - Archive ouverte HAL Access content directly
Journal Articles Leukemia & lymphoma Year : 2017

Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.

Abstract

This prospective non-interventional study assessed the management of relapsed/refractory CLL after one or two treatments with rituximab, and retreatment with a rituximab-based regimen. An interim analysis was performed at the end of the induction period in 192 evaluable patients. Median age was 72 years [35-89], first relapse (55%), and second relapse (45%). Rituximab administered during first (68%), second (92%), or both treatment lines (20%). R-bendamustine administered in 56% of patients, R-purine analogs (21%), and R-alkylating agents (19%). The overall response rate (ORR) was 74.6%, in favor of R-purine analogs (90%), R-bendamustine (75%), and R-alkylating agents (69%). Lower ORR in Del 17p patients (43%) and third time rituximab (31%). Most frequent adverse events were hematological (23% patients) including neutropenia (11%) and infections (12%); grade 3/4 AEs (23% patients), mainly hematological (18%); death during induction treatment (7%). This first large study focusing on relapsed/refractory CLL patients retreated with rituximab-based regimens is still ongoing.
No file

Dates and versions

hal-01529152 , version 1 (30-05-2017)

Identifiers

Cite

Driss Chaoui, Sylvain Choquet, Laurence Sanhes, Béatrice Mahé, Maya Hacini, et al.. Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.. Leukemia & lymphoma, 2017, 58 (6), pp.1366-1375. ⟨10.1080/10428194.2016.1243673⟩. ⟨hal-01529152⟩
261 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More